Co-founder of Chai Discovery, a full-stack AI drug discovery company building 3D atomic models for molecule design. Raised $400M at $3.8B valuation from Index, Kleiner Perkins, Sequoia, Dimension. Models deployed in discovery programs at Eli Lilly, Novartis, Pfizer.
no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
Chai's 3D atomic models crossed the Rubicon in 2025, moving from 0.1% success rates to zero-shot antibody design deployed in real discovery programs at Eli Lilly, Novartis, and Pfizer. The company builds custom architectures (not fine-tuned LLMs) trained on protein sequencing/structure data and in-house generation, creating a full-stack platform where scientists can prompt targets and receive binders — solving in hours what took careers.